Kautzky-Willer A, Kamyar MR, Gerhat D, Handisurya A, Stemer G, Hudson S, Luger A, Lemmens-Gruber R: Sex-specific variations in metabolic manage, cardiovascular danger, and interventions in patients with kind two diabetes mellitus. Gend Med 2010, 7:571?83. 13. Pan WH, Cedres LB, Liu K, Dyer A, Schoenberger JA, Shekelle RB, Stamler R, Smith D, Collette P, Stamler J: Connection of clinical diabetes and asymptomatic hyperglycemia to danger of coronary heart illness mortality in males and women. Am J Epidemiol 1986, 123:504?16. 14. Pyorala K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987, 3:463?24. 15. Asztalos BF, Schaefer EJ: HDL in atherosclerosis: actor or bystender? Atherosclerosis 2003, 4(Suppl 1):21?9. 16. Hayden MR, Tyagi SC: Isolated low high density lipoprotein-cholesterol (HDL-C): implications of global risk reduction. Case report and systematic scientific critique. Cardiovasc Diabetol 2005, four(1):1. 17. Taskinen MR: Diabetic dyslipidemia: from fundamental investigation to clinical practice. Diabetologia 2003, 46:733?49. 18. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ: Distribution of ApoA-I-containing HDL subpopulations in sufferers with coronary heart disease. Arterioscler Thromb Vasc Biol 2000, 20:2670?676. 19. Pirillo A, Norata GD, Catapano AL: High-density lipoprotein subfractions what the clinicians really need to know. Cardiology 2013, 124:116?25. 20. Mackness MI, Durrington PN, Mackness B: The role of paraoxonase 1 activity in cardiovascular disease: prospective for therapeutic intervention. Am J Cardiovasc Drugs 2004, four:211?17. 21. Mertens A, Holvoet P: Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001, 15:2073?084. 22. Mangge H, Almer G, Truschnig-Wilders M, Schmidt A, Gasser R, Fuchs D: Inflammation, adiponectin, obesity and cardiovascular danger. Curr Med Chem 2010, 17:4511?520.23. Huang SS, Huang PH, Chen YH, Chiang KH, Chen JW, Lin SJ: Association of adiponectin with future cardiovascular events in individuals following acute myocardial infarction. J Atheroscler Thromb 2010, 17:295?03. 24. Hagberg CE, Mehlem A, Falkevall A, Muhl L, Fam BC, Orts er H, Scotney P, Nyqvist D, Sam E, Lu L, Stone-Elander S, Proietto J, Andrikopoulos S, Sj olm A, Nash A, Eriksson U: Targeting VEGF-B as a novel therapy for insulin resistance and form 2 diabetes.Methyl 1H-1,2,3-triazole-4-carboxylate Price Nature 2012, 490(7420):426?30. 25. Li Q, Yang Z, Lu B, Wen J, Ye Z, Chen L, He M, Tao X, Zhang W, Huang Y, Zhang Z, Qu S, Hu R: Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with variety two diabetes. Cardiovasc Diabetol 2011, ten:72. 26. Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC: Higher serum uric acid as a novel risk aspect for type 2 diabetes.EPhos Pd G4 site Diabetes Care 2008, 31(two):361?62.PMID:23537004 27. Kaushik M, Sontineni SP, Hunter C: Cardiovascular disease and androgens: a overview. Int J Cardiol 2010, 142:eight?four. 28. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J: Risks and advantages of estrogen plus progestin in healthy postmenopausal girls: principal benefits from the women’s well being initiative randomized controlled trial. JAMA 2002, 288:321?33. 29. Casiglia E, Tikhonoff V, Caffi S, Bascelli A, Schiavon L, Guidotti F, Saugo M, Giacomazzo M, Martini B, Mazza A, D’este D, Pessina AC: Menopause does not have an effect on blood stress and risk profile, and menopausal girls d.